Welcome to the European Journal of Cancer’s Advances in Melanoma Resource Centre. The Resource Centre, edited by Prof. Reinhard Dummer, Dr. Paolo Ascierto and Dr. James Larkin, will provide you with the latest research on melanoma, including a selection of original research and review articles from some of the world’s leading journals, case studies, and other educational material. New articles will be added to the Resource Centre regularly and are openly available to our readers.

What is a Resource Centre?

A Resource Centre is a freely accessible platform, designed for healthcare professionals, that aims to increase clinical knowledge in a specific medical specialty by disseminating important new research and clinical developments more broadly. Resource Centres are all independently editorially controlled, provided in collaboration with established medical journals, hosted and managed by Elsevier, and funded by educational grants from societies and other organizations, such as medical or pharmaceutical companies.

Paper of the Month

August 2014

  • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

    Authors: Caroline Robert, Antoni Ribas, Jedd D Wolchok, F Stephen Hodi, Omid Hamid, Richard Kefford, Jeffrey S Weber, Anthony M Joshua, Wen-Jen Hwu, Tara C Gangadhar, Amita Patnaik, Roxana Dronca, Hassane Zarour, Richard W Joseph, Peter Boasberg, Bartosz Chmielowski, Christine Mateus, Michael A Postow, Kevin Gergich, Jeroen Elassaiss-Schaap, Xiaoyun Nicole Li, et al.

    Editor's comments:
    By Dr. James Larkin: Caroline Robert and colleagues report a randomised comparison of 2 doses of the anti-programmed-death-receptor-1 agent pembrolizumab in ipilimumab-refractory advanced melanoma. This was an expansion cohort of a Phase 1 trial in which 173 patients were treated with pembrolizumab 2mg/kg (n=89) or 10mg/kg (n=84) every 3 weeks. Patients with BRAF mutant tumours were only eligible if prior treatment with a BRAF or MEK inhibitor or both had been given. Treatment was well tolerated with about a third of patients experiencing fatigue, a quarter pruritus and a fifth rash of any grade in both dosing groups. Grade 3 fatigue was the only drug-related adverse event reported in more than 1 patient (3% of patients in the 2mg/kg group). Median follow up duration was 8 months and overall response rate, the primary endpoint of the study, was 26% at both doses with 88% of responses ongoing at the time of analysis. These data provide further evidence of the safety and efficacy of anti-PD1 therapy in a group of advanced melanoma patients with limited treatment options. Although this a randomised study, the randomisation was between different doses of pembrolizumab. Randomised data comparing anti-PD1 therapy with standard of care agents are eagerly awaited.


About the editor

  • Professor Reinhard G. Dummer

    Professor Dummer is Vice-Chairman of the Department of Dermatology and Head of the Skin Cancer Unit at the University Hospital of Zürich.

  • Dr. Paolo A. Ascierto

    Dr. Paolo A. Ascierto is Director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute ‘Fondazione G. Pascale’, in Naples, Italy.

  • The Role of the Editor

    The editors of the Advances in Melanoma Resource Centre are appointed on the recommendation of the journal’s Editor Team, led by Editor-in-Chief, Alexander M. M. Eggermont. Professor Dummer, Dr. Ascierto and Dr. Larkin select journal articles that have been previously peer-reviewed and accepted for publication in the EJC and other oncology and dermatology journals on melanoma and related topics, building a comprehensive collection of peer-reviewed content in this area.

    The editorial independence of the resource centre is of the utmost importance.
    The journal articles and other material published on the resource centre have been selected solely by Professor Dummer and Dr. Ascierto, independently and without influence from Elsevier or the sponsor.

  • Dr. James Larkin

    Dr James Larkin, FRCP PhD is a Medical Oncologist specialising in the treatment
    of patients with cancer of the kidney and cancers of the skin, including melanoma.

Congress planner


  • 3 - 6 September

    United Kingdom, Edinburgh

    The 15th World Congress on Cancers of the Skin

    More information

  • 4 - 7 September

    Singapore, Singapore

    XXII International Pigment Cell Conference

    More information

  • 18 - 21 September

    Bosnia & Herzegovina, Sarajevo

    1st Euro-Asian Melanoma Congress

    More information

  • 13 - 16 November

    Swziterland, Zurich

    Society for Melanoma Research - 2014 International Congress

    More information

back to top
back to top